SUGAR LAND--February 9, 2017--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--It was a wary group of Big Pharma heavyweights that made their way to Washington D.C. last week. Summoned by President Donald Trump, the industry and market collectively held their breath, uncertain of what lay ahead following the new president's recent recriminations against the industry. Instead of a visit to the woodshed, Big Pharma came away with cause to celebrate.
Within this article: Potential implications of meeting between President Donald Trump and leaders of big pharmaceutical companies.
Additional companies: Pfizer (NYSE:PFE), Merck & Co Inc. (NYSE:MRK), Amgen Inc. (NASDAQ:AMGN), Eli Lilly & Company (NYSE:LLY), Celgene Corp. (NASDAQ: CELG), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS)
(All Fields Required)
Site-wide Scheduled Maintenance for September 27, 2025 from 12 P.M. to 6 P.M. CDT. Expect intermittent web site availability during this time period.
×